课题基金 / 基金详情

Growth and differentiation signals of the erythropoietin receptor

Growth and differentiation signals of the erythropoietin receptor
促红细胞生成素受体的生长和分化信号
批准号:
09470036
负责人:
YOSHIMURA Akihiko
金额:
$8.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999

项目摘要

项目成果

YOSHIMURA Akihiko的其他基金

相似基金

相关文献

中文摘要
翻译
为了鉴定对造血干细胞自我更新或分化很重要的c-kit新型底物,通过荧光激活细胞分选仪对小鼠的CD34阴性、Sca-1阳性、c-KIT阳性和谱系标记阴性(CD34-Sca-1 c-Kit-Lin-)细胞进行分选,并构建了两个杂交cDNA文库。通过以c-kit为诱饵筛选,我们克隆了一个新的cDNA,设计了STAP-1,编码具有Pleckstrin同源结构域、Src同源2结构域和多个酪氨酸磷酸化位点的接头蛋白。 RT-PCR分析显示STAP-1表达仅限于表达c-kit的骨髓细胞级分中,并且在CD34-Sca-1 c-Kit Lin-造血干细胞富集级分中观察到最高表达。小鼠骨髓细胞系 M1 表达高水平的 STAP-1。然而,该表达受到白血病抑制因子的强烈抑制,该因子诱导 M1 细胞的单核细胞分化,这表明 STAP-1 与未分化的细胞类型相关。在 293 细胞中,STAP-1 被激活的 c-kit 酪氨酸磷酸化。体外结合实验表明,STAP-1 SH2 结构域与包括 c-kit 和 STAT5 在内的多种酪氨酸磷酸化蛋白相互作用。表明 STAP-1 在造血干细胞中充当 c-kit 下游的衔接分子。CIS3/SOC53 是含有 SH2 的小蛋白,可与 JAK 酪氨酸激酶相互作用并抑制 JAK 酪氨酸激酶。在胚胎发育过程中,CIS53/SOCS-3 在胎儿肝脏的一些(但不是全部)红系细胞中高度表达,并且这种表达独立于促红细胞生成素 (EPO) 信号传导。转基因介导的组成型表达阻断胎儿红细胞生成,导致胚胎致死。 CIS3/SOCS-3 的缺失会导致 12-16 天的胚胎死亡,并伴有明显的红细胞增多症。而且,胎肝祖细胞个体体外增殖能力大大增强。结果表明CIS3/SOCS-3在负调节胎儿肝脏造血中发挥着关键作用。我们还证明,CIS3-SOCS3 与表达 EPOR (BF-ER) 的脾脏红系祖细胞和表达 EPOR (BF-ER) 的 Ba/F3 细胞中的 EPO 受体以及 JAK2 结合,表明 CIS3/SOCS3 对 EPO 信号传导具有特定的负调节作用。较少的
英文摘要
To identify the novel substrate of c-kit which is important for hematopoietic stem cell self-renewal or differentiation, CD34-negative, Sca-1 positive, c-KIT-positive, and Lineage marker-negative (CD34-Sca-1+c-Kit-Lin- )cells were sorted by a fluorescence-activated cell sorter from mouse and two hybrid cDNA library was constructed. By the screening using c-kit as bait, we cloned a novel cDNA, designed STAP-1, encoding an adaptor protein with a Pleckstrin homology domain, Src homology 2 domain, and a number of tyrosine phosphorylation sites. RT-PCR analysis revealed that STAP-1 expression is restricted in bone marrow cell fraction expressing c-kit, and the highest expression was observed in CD34-Sca-1+c-Kit+Lin- hematopietic stem cell enriched fraction. Murine myeloid cell line, M1 expressed high level of STAP-1. However, the expression was strongly repressed in response to leukemia inhibitory factor which induced monocytic differentiation of M1 cells, suggesting that STAP-1 is associat … More ed with undifferentiated cell type. In 293 cells, STAP-1 was tyrosine phosphorylated by activated c-kit. In vitro binding assay suggested that STAP-1 SH2 domain interacted with several tyrosine phosphorylated proteins including c-kit and STAT5.There suggest that STAP-1 functions as an adaptor molecule downstream of c-kit in hematopoietic stem cells.CIS3/SOC53 are small SH2 containing proteins that interact with and inhibit JAK tyrosine kinases. During embryonic development, CIS53/SOCS-3 is highly expressed in some but no all erythroid lineage cells of the fetal liver and this expression is independent of erythropoietin (EPO) signaling. Transgene mediated constitutive expression blocks fetal erythropoiesis resulting in an embryonic lethality. Deletion of CIS3/SOCS-3 results in an embryonic lethality at 12-16 days that is associated with a marked erythrocytosis. Moreover, the individual in vitro proliferative capacity of fetal liver progenitors is greatly increased. The results demonstrate that CIS3/SOCS-3 play a critical role in negatively regulating fetal liver hematopoiesis. We also demonstrated that CIS3-SOCS3 bound to the EPO receptor as well as JAK2 in erythroid progenitors from spleen and Ba/F3 cells expressing the EPOR (BF-ER), suggesting a specific negative regulatory effect of CIS3/SOCS3 on EPO signaling. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yasukawa H, et al.: "The JAK-Binding Protein JAB Inhibits Janus Tyrosine Kinase Activity Through Binding in the Activation Loop."EMBO J.. 18, 5. 1309-1320 (1999)
Yasukawa H 等人:“JAK 结合蛋白 JAB 通过与激活环中的结合抑制 Janus 酪氨酸激酶活性。”EMBO J.. 18, 5. 1309-1320 (1999)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Wakioka T,et al.: "APS,an Adaptor Protein Containing PH and SH2 Domains Inhibits the JAK-STAT Pathway in Collaboration with c-Chl" Leukemia. in press. (1999)
Wakioka T 等人:“APS,一种含有 PH 和 SH2 结构域的接头蛋白,与 c-Chl 协同抑制 JAK-STAT 通路”白血病。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Immune systems involved in the resolution of inflammation and tissue repair
  • 批准号:
    17H06175
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
  • 资助金额:
    $131.71万
  • 财政年份:
    2017
  • 负责人:
    YOSHIMURA Akihiko
  • 依托单位:
Identification of Cellular Signaling Mechanism that regulates inflammation and tissue repairing
  • 批准号:
    25221305
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
  • 资助金额:
    $122.8万
  • 财政年份:
    2013
  • 负责人:
    YOSHIMURA Akihiko
  • 依托单位:
Systemic Biology of T cell differentiation
  • 批准号:
    25670234
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
  • 资助金额:
    $2.5万
  • 财政年份:
    2013
  • 负责人:
    YOSHIMURA Akihiko
  • 依托单位:
Systembiology of T-cell differentiation
  • 批准号:
    23659242
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
  • 资助金额:
    $2.33万
  • 财政年份:
    2011
  • 负责人:
    YOSHIMURA Akihiko
  • 依托单位:
国内基金
海外基金
基于ACO2-JAK/STAT3信号轴探讨芫荽及其活性成分改善动脉粥样硬化的药理机制研究
  • 批准号:
    2026JJ82274
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    侯凯
  • 依托单位:
SIRT6通过去乙酰化修饰调控JAK2/STAT1信号通路介导细胞焦亡途径促进脊髓损伤进展的分子机制研究
  • 批准号:
    2026JJ81836
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    陈朝晖
  • 依托单位:
黄芪多糖调控JAK2/STAT3信号通路抵抗PD-L1介导的卵巢癌细胞免疫逃逸研究
益气活血方调控雪旺细胞外泌体/JAK2/STAT3通路介导巨噬细胞极化改善糖尿病足溃疡的作用机制研究
  • 批准号:
    2026JJ80487
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    于洪海
  • 依托单位: